Form 8-K - Current report:
SEC Accession No. 0001193125-24-279016
Filing Date
2024-12-16
Accepted
2024-12-16 07:07:31
Documents
14
Period of Report
2024-12-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d866245d8k.htm   iXBRL 8-K 31435
2 EX-99.1 d866245dex991.htm EX-99.1 9391
  Complete submission text file 0001193125-24-279016.txt   169355

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA kalv-20241216.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE kalv-20241216_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kalv-20241216_pre.xml EX-101.PRE 11264
16 EXTRACTED XBRL INSTANCE DOCUMENT d866245d8k_htm.xml XML 3648
Mailing Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142
Business Address 55 CAMBRIDGE PARKWAY SUITE 901E CAMBRIDGE MA 02142 (857) 999-0075
KalVista Pharmaceuticals, Inc. (Filer) CIK: 0001348911 (see all company filings)

EIN.: 200915291 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-36830 | Film No.: 241550122
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)